Lone Star Bio

Found 17,151 articles

• XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

  5/17/2023

  Xbiotech Inc. announced that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not greater than $4.00 nor less than $3.80 per common share, to the seller in cash, less any applicable withholding taxes and without interest.

• Monogram Orthopaedics Announces Closing of Public Offering of $17,216,147

  5/17/2023

  Monogram Orthopaedics Inc. announced it raised $17,216,147 through the sale of 2,374,641 shares of its Class A Common Stock priced at $7.25 per share.

• Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer

  5/17/2023

  Indapta Therapeutics, Inc. today announced that the company has reached agreement with the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application to commence its first-in-human phase 1 trial in patients with multiple myeloma and lymphoma anticipated to begin in the second half of 2023.

• Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET

  5/17/2023

  Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET.

• Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease

  5/16/2023

  Coya Therapeutics, Inc. today reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with AD.

• QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®

  5/16/2023

  QSAM Biosciences, Inc. (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, and RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the U.S., announced today a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam® (Samarium-153 DOTMP).

• EPI’s Pulvinar Neuro is Awarded $3 Million NIH Grant for Transcranial Stimulation Research

  5/16/2023

  Pulvinar Neuro was awarded a grant from the National Institutes of Health (NIH) to further its research in transcranial stimulation (TCS) as a potential treatment for psychiatric disorders.

• The Caris Precision Oncology Alliance Welcomes Robert H. Lurie Comprehensive Cancer Center of Northwestern University

  5/16/2023

  Caris Life Sciences® announced that Robert H. Lurie Comprehensive Cancer Center of Northwestern University has joined the Caris Precision Oncology Alliance™.

• Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas

  5/16/2023

  Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced its collaboration in a Phase 1 clinical trial for tegavivint in patients with relapsed or refractory c-Myc-overexpressing large B-cell lymphomas.

• Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

  5/16/2023

  Salarius Pharmaceuticals, Inc. announced that it has closed its previously announced private placement for the issuance and sale of an aggregate of 3,636,364 shares of its common stock, Series A-1 warrants to purchase up to an aggregate of 3,636,364 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 3,636,364 shares of common stock at a purchase price of $1.65 per share and accompanying warrants, priced at-the-market under Nasdaq rules.

• Virogentics Inc. Receives Report from Bulgarian Academy of Sciences Administration of ITV-1 to Begin First Week in June 2023

  5/16/2023

  Enzolytics, Inc. announced that the Company's wholly owned subsidiary, Virogentics (VIRO), has received the analysis report from the Bulgarian Academy of Sciences determining the protein concentration, native enzyme concentration and peptide analysis, and amino acid sequence for Module 3 for the permitting by the European Medicine agency ("EMA ").

• Triumvira Immunologics to Present Clinical Data from Phase I/II Trial TACTIC-2 Investigating TAC01-HER2 at the 2023 ASCO Annual Meeting

  5/16/2023

  Triumvira Immunologics today announced that the Company will be presenting clinical data on its lead asset TAC01-HER2 for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors at the 2023 American Society Of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, June 2-6.

• CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/15/2023

  CNS Pharmaceuticals, Inc. today reported its financial results for the quarter ended March 31, 2023 and provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer.

• Savara Reports First Quarter Financial Results and Provides Business Update

  5/15/2023

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2023 and provided a business update.

• The Ear Institute of Texas Celebrates its 20th Anniversary of Providing Medical and Surgical Ear, Nose and Throat Care

  5/15/2023

  The Ear Institute of Texas, which is a Parallel ENT & Allergy supported practice, proudly announces their 20th anniversary of providing exceptional medical and surgical care for ear, nose, and throat disorders, including care for dizziness and audiology services.

• Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation

  5/15/2023

  Castle Biosciences, Inc. today announced that it has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare” award in the seventh annual MedTech Breakthrough Awards program for its innovative TissueCypher® Barrett’s Esophagus test.

• Retractable Technologies, Inc. Results for the Period Ended March 31, 2023

  5/15/2023

  Retractable Technologies, Inc. reports total net sales of $11.0 million for the first three months of 2023 and an operating loss of $2.7 million for the period, as compared to total net sales for the same period last year of $44.7 million and an operating income of $9.7 million.

• Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma

  5/15/2023

  Hummingbird Bioscience announced it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001 in combination with cetuximab in squamous non-small cell lung carcinoma.

• Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

  5/15/2023

  Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2023 results and provided a business update.

• Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update

  5/15/2023

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the first quarter of 2023.